Skin vasculitis (purpura, cutaneous ulcers or others) at 18 and 24 months: number of affected patients · hepatitis C virus‐associated mixed cryoglobulinaemia
Rituximab showed no clear difference in skin vasculitis (purpura, cutaneous ulcers or others) at 18 and 24… compared with no rituximab (moderate certainty).
1 finding from 1 review
SCr at 18 months · hepatitis C virus‐associated mixed cryoglobulinaemia
1 finding from 1 review
Cryocrit at 12 months · hepatitis C virus‐associated mixed cryoglobulinaemia
1 finding from 1 review
Infusion reactions · hepatitis C virus‐associated mixed cryoglobulinaemia
Rituximab showed no clear difference in adverse effects ‐ infusion reactions: number of events compared with no rituximab (moderate certainty).
1 finding from 1 review
Activity outcomes BVAS: from 0 to 63 · hepatitis C virus‐associated mixed cryoglobulinaemia
1 finding from 1 review
Relapse at 3 months · SSNS in children
Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Relapse · SSNS in children
Rituximab probably leads to lower relapses at 6 months compared with placebo or control (moderate certainty).
2 findings from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: moderate to severe Infusion reactions · SSNS in children
Rituximab may leads to higher adverse effects: moderate to severe Infusion reactions compared with placebo or control (low certainty).
1 finding from 1 review
Adverse effects: severe infection · SSNS in children
Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).
1 finding from 1 review
Adverse effects: arthropathy · SSNS in children
Rituximab showed no clear difference in adverse effects: arthropathy compared with placebo or control (low certainty).
1 finding from 1 review
Death at 6 months · adults with renal vasculitis
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with renal vasculitis
Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Relapse · adults with renal vasculitis
Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).
1 finding from 1 review
Serious adverse events · adults with renal vasculitis
Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious infections · adults with renal vasculitis
Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Number of participants improved in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Rituximab may leads to higher number of participants improved in disability compared with placebo (low certainty).
1 finding from 1 review